KRAS mutant allele-specific imbalance in lung adenocarcinoma

[1]  Simion I. Chiosea,et al.  Higher Dosage of the Epidermal Growth Factor Receptor Mutant Allele in Lung Adenocarcinoma Correlates with Younger Age, Stage IV at Presentation, and Poorer Survival , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  H. Sasaki,et al.  Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Youngho Seo,et al.  Selective activation of p53-mediated tumour suppression in high-grade tumours , 2010, Nature.

[4]  Francisco J. Sánchez-Rivera,et al.  Stage-specific sensitivity to p53 restoration during lung cancer progression , 2010, Nature.

[5]  Simion I. Chiosea,et al.  EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. , 2010, Human pathology.

[6]  S. Dacic,et al.  Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas , 2010, Modern Pathology.

[7]  Calum MacAulay,et al.  Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells , 2009, PloS one.

[8]  M. Meyerson,et al.  In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. , 2009, American journal of clinical pathology.

[9]  L. Garraway,et al.  Oncogenic Activating Mutations Are Associated with Local Copy Gain , 2009, Molecular Cancer Research.

[10]  Michael Peyton,et al.  Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines , 2009, PloS one.

[11]  F. Siannis,et al.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.

[12]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[13]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[14]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[15]  Takayuki Kosaka,et al.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Barbacid,et al.  ras gene Amplification and malignant transformation , 1985, Molecular and cellular biology.

[17]  H. Varmus,et al.  A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells , 1983, Nature.

[18]  T. Bauer,et al.  Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas , 2010 .

[19]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[20]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[21]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[22]  E. Engel,et al.  A new genetic concept: uniparental disomy and its potential effect, isodisomy. , 1980, American journal of medical genetics.